BIFIDOBACTERIA FOR TREATING DIABETES AND RELATED CONDITIONS
This invention relates to new uses of Bifidobacteria (particularly, although not exclusively, probiotic Bifidobacteria), and to food products, feed products, dietary supplements and pharmaceutical formulations containing them. The bacteria are suitable for the treatment of diabetes (particularly Type 2 diabetes), obesity and related conditions, metabolic syndrome, insulin resistance, and impaired glucose metabolism and consequences thereof, lowering tissue inflammation, treating hepatitis, myositis and cardiovascular conditions.
1 - 44 . (canceled)
45 . A method of treating a disease or condition in a mammal, wherein:
the method comprises administering to a mammal in need of such treatment a combination of (i) Bifidobacterium animalis subsp. lactis strain 420 and (ii) an antidiabetic drug selected from a biguanide or a dipeptidyl peptidase-4 (DPP-4) inhibitor; and
the disease or condition is selected from:
(a) diabetes;
(b) metabolic syndrome;
(c) impaired glucose tolerance;
(d) reduced insulin sensitivity;
(e) reduced fed insulin secretion;
(f) elevated fasted insulin secretion;
(g) obesity;
(h) weight gain;
(i) elevated body fat mass.
46 . The method of claim 45 , wherein:
the method comprises treating diabetes, and
the diabetes is Type 2 diabetes.
47 - 51 . (canceled)
52 . The method of claim 45 , wherein the mammal in need of the treatment ingests a high-fat diet.
53 - 57 . (canceled)
58 . The method of claim 45 , wherein the Bifidobacterium animalis subsp. lactis strain 420 and antidiabetic drug are administered in combination with an additional bacterium of the genus Lactobacillus.
59 . The method of claim 58 , wherein the additional bacterium is of the species Lactobacillus acidophilus.
60 . The method of claim 59 , wherein the additional bacterium is Lactobacillus acidophilus strain NCFM (ATCC PTA-4797).
61 . The method of claim 45 , wherein the Bifidobacterium animalis subsp. lactis strain 420 and antidiabetic drug are administered in combination with a prebiotic.
62 . The method of claim 61 , wherein the prebiotic is polydextrose.
63 - 64 . (canceled)
65 . The method of claim 45 , wherein the antidiabetic drug is a biguanide.
66 . The method of claim 45 , wherein the antidiabetic drug is metformin.
67 . The method of claim 59 , wherein the antidiabetic drug is a biguanide.
68 . The method of claim 59 , wherein the antidiabetic drug is metformin.
69 . The method of claim 60 , wherein the antidiabetic drug is a biguanide.
70 . The method of claim 60 , wherein the antidiabetic drug is metformin.
71 . The method of claim 61 , wherein the antidiabetic drug is a biguanide.
72 . The method of claim 61 , wherein the antidiabetic drug is metformin.
73 . The method of claim 62 , wherein the antidiabetic drug is a biguanide.
74 . The method of claim 62 , wherein the antidiabetic drug is metformin.